Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210. The company is headquartered in Princeton, New Jersey.
Metrics to compare | SONN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSONNPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.6x | −1.2x | −0.6x | |
PEG Ratio | −0.01 | 0.02 | 0.00 | |
Price / Book | 1.7x | 3.1x | 2.6x | |
Price / LTM Sales | 80.9x | 20.6x | 3.1x | |
Upside (Analyst Target) | 3,601.4% | 494.3% | 55.8% | |
Fair Value Upside | Unlock | 8.5% | 7.3% | Unlock |